Evidence map›Paper›PMID 30191738›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2018

Novel group of tyrosyl-DNA-phosphodiesterase 1 inhibitors based on disaccharide nucleosides as drug prototypes for anti-cancer therapy.

Anastasia O Komarova, Mikhail S Drenichev, Nadezhda S Dyrkheeva, Irina V Kulikova, Vladimir E Oslovsky, Olga D Zakharova, Alexandra L Zakharenko, Sergey N Mikhailov, Olga I Lavrik

Open access · goldAbstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Anastasia O Komarovaa Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences , Novosibirsk , Russian Federation.
Mikhail S Drenichevc Engelhardt Institute of Molecular Biology, Russian Academy of Sciences , Moscow , Russian Federation.ORCID http://orcid.org/0000-0001-7624-8801
Nadezhda S Dyrkheevaa Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences , Novosibirsk , Russian Federation.ORCID http://orcid.org/0000-0002-8360-1041
Irina V Kulikovac Engelhardt Institute of Molecular Biology, Russian Academy of Sciences , Moscow , Russian Federation.
Vladimir E Oslovskyc Engelhardt Institute of Molecular Biology, Russian Academy of Sciences , Moscow , Russian Federation.
Olga D Zakharovaa Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences , Novosibirsk , Russian Federation.ORCID http://orcid.org/0000-0001-5980-8889
Alexandra L Zakharenkoa Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences , Novosibirsk , Russian Federation.
Sergey N Mikhailovc Engelhardt Institute of Molecular Biology, Russian Academy of Sciences , Moscow , Russian Federation.ORCID http://orcid.org/0000-0002-1363-9706
Olga I Lavrika Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences , Novosibirsk , Russian Federation.
Engelhardt Institute of Molecular Biology · RUInstitute of Chemical Biology and Fundamental Medicine · RUNovosibirsk State University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new class of tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors based on disaccharide nucleosides was identified. TDP1 plays an essential role in the resistance of cancer cells to currently used antitumour drugs based on Top1 inhibitors such as topotecan and irinotecan. The most effective inhibitors investigated in this study have IC

Indexed as

Antineoplastic AgentsCell ProliferationCells, CulturedDisaccharidesDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular StructureNucleosidesPhosphodiesterase InhibitorsPhosphoric Diester HydrolasesStructure-Activity RelationshipTopotecanAntineoplastic AgentsDisaccharidesNucleosidesPhosphodiesterase InhibitorsPhosphoric Diester HydrolasesTDP1 protein, humanTopotecanDisaccharide nucleosidesTDP1 inhibitortopotecantyrosyl-DNA phosphodiesterase 1

Identifiers

PMID30191738
PMCPMC6136360
OpenAlexW2891000482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.